Glenmark Pharmaceuticals Launches Phytonadione Injectable Emulsion
Glenmark Pharmaceuticals announced the launch of Phytonadione Injectable Emulsion USP, 10mg/ml single dose ampules by its US arm. This new drug is designed to address blood clotting issues stemming from Vitamin K deficiency. It is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K Injectable Emulsion USP, 10 mg/ml of Hospira, Inc.
Marc Kikuchi, the company's president and business head in North America, expressed enthusiasm about the launch, stating, "We are excited to announce the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."
According to IQVIA sales data for the 12 months ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million.
Promising Clinical Trial Results for ISB 2001
In related news, Glenmark Pharmaceuticals shared initial results from the Phase 1 study of its Trispecific TREAT Antibody, ISB 2001, targeting heavily pretreated Multiple Myeloma patients. As of October 1, 2024, data from 20 patients showed an overall response rate (ORR) of 75% across all doses tested, which ranged from 0.005 to 1.2 mg per kg. The study also reported a stringent complete remission (sCR) and complete remission (CR) rate of 20%.
Glenmark highlighted that the ISB 2001 could compare favorably with approved bispecific options, indicating a potential new avenue for treatment in Multiple Myeloma.
Market Reaction
Following these announcements, Glenmark Pharma shares experienced a slight increase, trading 0.5% higher at ₹1,511.15 apiece. Over the past year, the stock has seen a significant gain of 75.92%, reflecting investor confidence in the company's growth and innovation in the pharmaceutical sector.
